Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET
Company Participants
Ray Furey - EVP, General Counsel and Corporate Secretary
Raul Rodriguez - President and CEO
Dave Santos - Chief Commercial Officer
Lisa Rojkjaer - Chief Medical Officer
Dean Schorno - CFO
Conference Call Participants
Yigal Nochomovitz - Citi
Kristen Kluska - Cantor
Joe Pantginis - H.C. Wainwright
Operator
Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Second Quarter 2024. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel, and Corporate Secretary.
Thank you, Mr. Furey. You may begin.
Ray Furey
Welcome to our second quarter 2024 financial results and business update conference call. The financial press release for the second quarter of 2024 was issued a short while ago and can be viewed along with the slides for this presentation in the news and events section of our investor relations site on Rigel.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development.
These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on form 10-K for the year ended December 31st, 2023, and subsequent filings with the SEC including quarter two quarterly report on form 10-Q on file with the SEC. Any forward-looking statements are made only as of today's date and we undertake no obligation to update these forward-looking statements to reflect subsequent events or
- Read more current RIGL analysis and news
- View all earnings call transcripts